Key Takeaways: The stimulant shortage reveals critical gaps in ADHD treatment, especially for adults, with rising diagnoses and limited clinical guidance complicating care. Despite increased production quotas, DEA-imposed caps restrict supply, failing to meet rising demand for ADHD medications. Critics argue DEA quotas are overly restrictive, hindering access for patients with ADHD and exacerbating the shortage. Calls for DEA reform emphasize prioritizing patient needs over concerns about misuse, aiming to resolve the ongoing medication shortage.